The effect of different dosage of vitamin D supplementation in early life on the expression of vitamin D receptor (VDR) on the lung in rat with asthma

2012 ◽  
Vol 13 ◽  
pp. S46
Author(s):  
L.Y. Chen ◽  
J.G. Hong ◽  
X.J. Zhou ◽  
X. Li ◽  
Z. Li
Nutrients ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1500
Author(s):  
Jabulani R. Ncayiyana ◽  
Leonardo Martinez ◽  
Elizabeth Goddard ◽  
Landon Myer ◽  
Heather J. Zar

Early-life vitamin D deficiency is associated with adverse child health outcomes, but the prevalence of vitamin D deficiency and its correlates in infants remains underexplored, particularly in sub-Saharan Africa. We aimed to investigate the prevalence of vitamin D deficiency and its correlates among young infants in South Africa. This study included 744 infants, aged 6–10 weeks from the Drakenstein Child Health Study, a population-based birth cohort. Infants were categorized into distinct categories based on serum 25(OH)D concentration level including deficient (<50 nmol/L), insufficient (50–74 nmol/L), and sufficient (≥75 nmol/L). Using multivariable Tobit and logistic regression models, we examined the correlates of serum 25(OH)D3 levels. The overall prevalence of vitamin D deficiency was 81% (95% confidence intervals (CI]) 78–83). Multivariable regression analysis showed that serum 25(OH)D3 concentration was independently associated with study site, socioeconomic status, and sex. Birth in winter and breastfeeding were the strongest predictors of lower serum 25(OH)D3 concentration levels. Compared to non-breastfed children, children breastfed were at higher risk of vitamin D deficiency (AOR, 1.96; 95% CI, 1.04–3.67) and breastfeeding for more than one month was associated with greater likelihood of vitamin D deficiency (AOR, 5.40; 95% CI, 2.37–12.32) and lower vitamin D concentrations (−16.22 nmol/L; 95% CI, −21.06, −11.39). Vitamin D deficiency in infants is ubiquitous, under-recognised, and strongly associated with season of birth and breastfeeding in this setting. Nutritional interventions with vitamin D supplementation in national health programs in low- and middle-income countries are urgently needed to improve early-life vitamin D status in infants.


2018 ◽  
Vol 21 (2) ◽  
pp. 12-22 ◽  
Author(s):  
Lilit V. Egshatyan ◽  
Natalya G. Mokrisheva

Background: secondary hyperparathyroidism (SHPT) is an early complication of chronic kidney disease (CKD). Maintaining the level of 25(OH)D and parathyroid hormone concentrations in the target range reduce its associated complications (fractures and cardiovascular calcification). Aims: to examine the effectiveness of vitamin D supplementation and selective vitamin D receptor agonists treatment on SHPT in CKD. Material and methods: prospective observational study to evaluate the efficacy and safety of vitamin D therapy SHPT in 54 in patients with CKD. The first phase (24 weeks) – treatment of suboptimal 25-hydroxycalciferol (25(OH)D) levels. The second (16 weeks) – treatment colecalciferol-resistant SHPT by combination of cholecalciferol with paricalcitol. Blood samples were taken to assess parathyroid hormone (PTH), 25(OH)D, creatinine, calcium, phosphorus levels and calcium excretion. Results: After 8 weeks of cholecalciferol treatment all patients achieved 25(OH)D levels above 20 ng/ml, however 78% of patients still had SHPT. After 16 weeks, the decrease of PTH was achieved in all patients, but significantly only in patients with CKD 2 (19.2%, p< 0.01) and 3 (31%, p <0.05), compared with CKD 4 (17%, p >0.05). After 24 weeks of therapy, PTH normalized in all patients with CKD 2, in 15 (79%) with CKD 3 and in 9 (50%) patients with CKD 4. Cholecalciferol treatment resulted in a substantial increase in 25(OH)D levels with minimal or no impact on calcium, phosphorus levels and kidney function. After 24 weeks we initiated combination therapy (cholecalciferol and paricalcitol) for patients with colecalciferol-resistant SHPT (n=13). PTH levels decreased from 149.1±13.4 to 118.2±14.1 pg/ml at 8 weeks, and to 93.1±9.7 pg/ml (p <0.05) at 16 weeks of treatment. No significant differences in serum calcium, phosphorus or urinary calcium levels. Normalization of PTH was achieved in all patients with CKD 3 and in 8 patients with stage 4. One patient with CKD 4 needed an increase in paricalcitol dose. Conclusion: Cholecalciferol can be used in correcting vitamin D deficiency in patients with all stages of CKD, however, its effectiveness in reducing PTH in stage 4 is limited. Selective analogs, such as paricalcitol, were well-tolerated and effectively decreased PTH levels.


2020 ◽  
Vol 113 (1) ◽  
pp. 104-112
Author(s):  
Joshua Garfein ◽  
Kerry S Flannagan ◽  
Sheila Gahagan ◽  
Raquel Burrows ◽  
Betsy Lozoff ◽  
...  

ABSTRACT Background Vitamin D deficiency is associated with obesity-related conditions, but the role of early life vitamin D status on the development of obesity is poorly understood. Objectives We assessed whether serum 25-hydroxyvitamin D [25(OH)D] at age 1 y was related to metabolic health through adolescence. Methods We quantified serum 25(OH)D in samples obtained at age 1 y from 306 participants in a cohort study in Santiago, Chile. Anthropometry was performed at ages 5, 10, and 16/17 y. At 16/17 y, we determined body composition using DXA and quantified metabolic parameters in a blood sample. We examined the associations of infancy 25(OH)D with BMI-for-age z-score (BMIZ) at ages 5, 10, and 16/17 y; with percentage fat and percentage lean body mass at age 16/17 y; and with a metabolic syndrome (MetS) score and its components at age 16/17 y. Results Infancy 25(OH)D was inversely associated with BMIZ in childhood. Every 25-nmol/L difference in 25(OH)D was related to an adjusted 0.11 units lower BMIZ at age 5 y (95% CI: −0.20, −0.03; P = 0.01) and a 0.09 unit lower BMIZ change from ages 1 to 5 y (95% CI: −0.17, −0.01; P = 0.02). Also, every 25-nmol/L 25(OH)D in infancy was associated with an adjusted 1.3 points lower percentage body fat mass (95% CI: −2.2, −0.4; P = 0.005) and an adjusted 0.03 units lower MetS score (95% CI: −0.05, −0.01; P = 0.01) at age 16/17 y, through inverse associations with waist circumference and the HOMA-IR. Conclusions Serum 25(OH)D at age 1 y is inversely associated with childhood BMIZ, percentage body fat at age 16/17 y, and a MetS score at age 16/17 y. Intervention studies are warranted to examine the effects of vitamin D supplementation in early life on long-term cardiometabolic outcomes.


2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Nasser M. Al-Daghri ◽  
Abdul Khader Mohammed ◽  
Omar S. Al-Attas ◽  
Mohammed Ghouse Ahmed Ansari ◽  
Kaiser Wani ◽  
...  

2020 ◽  
Vol 10 (4) ◽  
pp. 174-180
Author(s):  
Olha Yakovleva ◽  
Olha Nikolova

The review presents information on variants of Vitamin D receptor’s genetic polymorphism, ensuring the direct physiolo­gical effects of the Vitamin via stimulation of nuclear cellular me­chanisms. The article was aimed at raising awareness of the glo­bal scientific advances in the field of Vitamin D receptor’s genetic polymorphism and its association with bronchopulmonary patho­logy in various regions of the planet. The search of scientific refe­rences was carried out in the Scopus, Web of Science, The Cochrane Library, Pubmed, ResearchGate, Russian Science Citation Index (RINC) information databases. The regulatory potential of the Vitamin D active hormonal effects in the bronchopulmonary patho­logy, especially in bronchial asthma (BA), remains unclear in terms of its pathogenetic links. Individual alleles inherent in the receptor genetics were studied, primarily in children with BA across the world. The results were compared as to levels of Vitamin D supplementation, BA symptoms and course The divergences were found in the four variants of alleles: Fok1, Apal, BsmI, TaqI. Those divergences prevail in the individual ethnic populations, limiting our capacities of drawing unambiguous conclusions, although the relationship between the course of BA and the deficient Vitamin’s status remains predominant. It is necessary to widen the database prospectively, to clarify the genetic variants of all the components involved in the metabolism and the Vitamin’s effects (transporter proteins, cytochrome P450 and vitamin D receptor) while the research geography is also expanding in the world.


2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Francesca Marini ◽  
Fernanda Falcini ◽  
Stefano Stagi ◽  
Sergio Fabbri ◽  
Simone Ciuffi ◽  
...  

Abstract Juvenile idiopathic arthritis (JIA) is the most common chronic arthritis of children and adolescents. Autoimmune mechanisms are suspected to have a central role in its development. Vitamin D is an immuno-modulator in a variety of conditions, including autoimmune diseases. Low levels of vitamin D have commonly been found in JIA patients, but the influence of this hormone insufficiency in JIA pathogenesis is still unclear. Vitamin D receptor (VDR) mediates a great majority of vitamin D biological activities; specific polymorphisms of the VDR gene have been associated with different biologic responses to vitamin D. In this study, we analysed clinical characteristics of a cohort of 103 Italian JIA patients. The distribution of VDR polymorphisms in affected patients versus healthy controls was evaluated, as well as if and how these polymorphic variants associate with different disease presentations (active disease vs non-active disease), different JIA subtypes, serum levels of 25-hydroxy-vitamin D and parathyroid hormone (PTH), and lumbar spine Z-score values (osteopenia vs normal bone mineral density). A great majority of our JIA patients (84.5%) showed a suboptimal vitamin D status, in many cases (84.1%) not solved by vitamin D supplementation. Vitamin D status resulted to be independent of VDR genotypes. ApaI genotypes showed a highly significant different distribution between JIA patients and unaffected controls, with both the TT genotype and the T allele significantly more frequent in patient group.


Sign in / Sign up

Export Citation Format

Share Document